WCLC 2025 - Posters & ePosters-P3.12.08 Weight Gain Induced by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small Cell Lung Cancer: A Meta-Analysis and a Meta-Regression Study

P3.12.08 Weight Gain Induced by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small Cell Lung Cancer: A Meta-Analysis and a Meta-Regression Study

Back to course

Pdf Summary

This meta-analysis and meta-regression study investigates weight gain (WG) associated with tyrosine kinase inhibitors (TKIs) used in treating oncogene-addicted non-small cell lung cancer (NSCLC). Through a systematic literature search across PubMed, Scopus, Cochrane, and conference resources (ESMO, ASCO, WCLC), studies reporting WG as an adverse event were identified. Notably, WG was rarely reported before 2017 but has since emerged as a significant treatment-related effect.<br /><br />The pooled incidence of WG among NSCLC patients treated with TKIs was 17% (95% CI: 11%-24%), with substantial heterogeneity (I²=96%) due to variability across studies and TKI types. Among TKIs, ALK inhibitors showed the strongest association with WG. Lorlatinib demonstrated the highest WG incidence at 36% (95% CI: 26%-46%), followed by alectinib at 15% and crizotinib at 5%. EGFR inhibitors osimertinib and erlotinib had the lowest WG incidence. The meta-regression analysis revealed no significant correlation between WG and patient-specific factors such as gender, age, or performance status (ECOG PS), indicating the effect is likely drug-specific.<br /><br />The study highlights the clinical importance of recognizing WG as an adverse event, given its potential impact on body composition, metabolic health, quality of life, and long-term outcomes for NSCLC patients. As WG monitoring has not been routine, the authors advocate for prioritizing appropriate surveillance and lifestyle interventions to manage this side effect effectively. The findings emphasize the unique WG profile of lorlatinib among ALK inhibitors and call for further research to understand underlying mechanisms and clinical consequences.<br /><br />In conclusion, this work underscores the need for clinicians to be aware of WG risk associated with specific TKIs, especially lorlatinib, and to incorporate WG monitoring and management strategies into treatment plans of oncogene-addicted NSCLC patients.

Asset Subtitle

Lorenzo Belluomini

Meta Tag

Speaker Lorenzo Belluomini

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

weight gain

tyrosine kinase inhibitors

TKIs

non-small cell lung cancer

NSCLC

ALK inhibitors

lorlatinib

meta-analysis

adverse events

oncogene-addicted